Novo Nordisk A/S (NVO) Projected to Post Earnings on Wednesday

Posted by Brian Himes on Oct 28th, 2026

Novo Nordisk A/S (NYSE:NVO – Get Free Report) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to post earnings of $0.7270 per share and revenue of $11.09 billion for the quarter. Investors can check the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO – Get Free Report) last released its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share (EPS) for the quarter. The company had revenue of $11.98 billion during the quarter. On average, analysts expect Novo Nordisk A/S to post $3.42 EPS for the current fiscal year and $3.42 EPS for the next fiscal year.

Novo Nordisk A/S Trading Down 0.6%

NVO opened at $38.44 on Wednesday. The business’s 50-day simple moving average is $41.65 and its 200-day simple moving average is $44.63. Novo Nordisk A/S has a one year low of $35.12 and a one year high of $64.16.

Novo Nordisk A/S Cuts Dividend

The company also recently declared a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. This represents a yield of 258.0%. This is a negative change from Novo Nordisk A/S’s previous dividend of $1.2751. The ex-dividend date of this dividend was Monday, August 17th.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on NVO shares. Barclays reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research note on Monday, September 7th. Berenberg Bank reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Monday, September 21st. Weiss Ratings cut Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Thursday, October 8th. Jefferies Financial Group reiterated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Monday, September 21st. Finally, Citigroup restated a “neutral” rating on shares of Novo Nordisk A/S in a research report on Friday, October 9th. Five analysts have rated the stock with a Buy rating, sixteen have given a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $59.44.

Read Our Latest Stock Report on Novo Nordisk A/S

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

Positive Sentiment: The U.S. FDA approved Novo Nordisk’s Awiqli as a once-weekly basal insulin for children aged 10 and older with type 2 diabetes. The less-frequent dosing option could improve convenience and expand the product’s commercial opportunity. Novo Nordisk Wins FDA Nod For Weekly Insulin In Children With Type 2 Diabetes
Positive Sentiment: Oddo BHF raised its price target for Novo Nordisk from DKK 221 to DKK 305, signaling improved confidence in the company’s outlook. Oddo BHF Raises Target for Novo Nordisk Stock
Positive Sentiment: Novo Nordisk continues executing a share-repurchase program of up to DKK 15 billion. Buybacks can support earnings per share and provide demand for the stock. Novo Nordisk Share Repurchase Programme
Positive Sentiment: Erste Group Bank modestly increased its FY2026 and FY2027 EPS forecasts to $3.30 and $3.27, respectively, although both remain below the broader $3.42 consensus estimate.
Neutral Sentiment: Healthcare stocks weakened broadly in late trading, indicating that part of Novo Nordisk’s recent pressure may reflect sector-wide risk aversion rather than company-specific news. Sector Update: Healthcare Stocks Decline Late Afternoon
Negative Sentiment: A U.S. judge refused Novo Nordisk’s request to block Eli Lilly’s Zepbound advertising. The ruling allows a major obesity-drug rival to continue comparative marketing, potentially intensifying competition and limiting Novo’s ability to challenge Lilly’s messaging. Novo Nordisk Denied Injunction Against Eli Lilly’s Advertising

About Novo Nordisk A/S

(Get Free Report)

Novo Nordisk A/S is a Danish pharmaceutical company headquartered in Bagsværd, Denmark. The company focuses on developing and manufacturing medicines and delivery systems for chronic diseases, with a primary emphasis on diabetes and obesity care.

Novo Nordisk offers a broad portfolio of insulin products, as well as glucagon-like peptide-1 (GLP-1) medicines used in diabetes management and weight treatment. Its well-known products include Ozempic and Rybelsus for type 2 diabetes, Wegovy for chronic weight management, and several modern and human insulin products.